Who are Remodulin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Uptravi, Flolan, FLOLAN injection with reformulated diluent, prostacyclin, Fundyl, Epalrestat,Mecobalamin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/treprostinil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Remodulin — Competitive Intelligence Brief

Remodulin (TREPROSTINIL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostacycline Vasodilator [EPC]. Area: Cardiovascular.

marketed Prostacycline Vasodilator [EPC] Prostacyclin receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Remodulin (TREPROSTINIL) — United Therap. Remodulin works by activating the prostacyclin receptor, which causes blood vessels to relax and widen.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Remodulin TARGET	TREPROSTINIL	United Therap	marketed	Prostacycline Vasodilator [EPC]	Prostacyclin receptor	2002-01-01
Uptravi	SELEXIPAG	AstraZeneca	marketed	Prostacyclin Receptor Agonist [EPC]	Prostacyclin receptor	2015-01-01
Flolan	EPOPROSTENOL	AstraZeneca	marketed	Prostacycline Vasodilator [EPC]	Prostacyclin receptor	1995-01-01
FLOLAN injection with reformulated diluent	FLOLAN injection with reformulated diluent	GlaxoSmithKline	marketed	Prostacyclin analog	Prostacyclin receptor (IP receptor)
prostacyclin	prostacyclin	United Therapeutics	marketed		P2Y purinoceptor 12, Prostacyclin receptor, Prostaglandin E2 receptor EP1 subtype
Fundyl	ENPROSTIL		marketed	enprostil	Prostacyclin receptor, Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP3 subtype
Epalrestat,Mecobalamin	Epalrestat,Mecobalamin	Xiangya Hospital of Central South University	marketed	Prostacyclin analog + Cobalamin derivative combination	Prostacyclin receptor (IP receptor) + Methylcobalamin-dependent enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostacycline Vasodilator [EPC] class)

AstraZeneca · 1 drug in this class
United Therap · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Remodulin — Competitive Intelligence Brief. https://druglandscape.com/ci/treprostinil. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab